A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France (original) (raw)
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
Holger Gothe
Patient Preference and Adherence, 2008
View PDFchevron_right
Faculty of 1000 evaluation for Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
John Eisman
F1000 - Post-publication peer review of the biomedical literature
View PDFchevron_right
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Ghada Fuleihan
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015
View PDFchevron_right
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis
Pablo Enríquez
Osteoporosis International, 2010
View PDFchevron_right
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Carrie McAdam-marx
Osteoporosis International, 2010
View PDFchevron_right
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials
Roberta Navickis
Osteoporosis International, 2010
View PDFchevron_right
Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis
Kelly Vogt
Therapeutics and Clinical Risk Management, 2011
View PDFchevron_right
Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence
john sampalis
Journal of Bone and Mineral Research, 2011
View PDFchevron_right
Adherence with brand versus generic bisphosphonates among osteoporosis patients: a new-user cohort study in the French National Healthcare Insurance database
Alexandra Dima
Scientific Reports
View PDFchevron_right
The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review
Jonathan Adachi
BMC Musculoskeletal Disorders, 2007
View PDFchevron_right
Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy
Laura Borgelt
International Journal of Women's Health, 2014
View PDFchevron_right
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women
Siew-Siang Chua
Journal of Clinical Pharmacy and Therapeutics, 2011
View PDFchevron_right
Adherence to Bisphosphonate Therapy in Postmenopausal Osteoporotic Women
Adina Turcu-Stiolica
Folia Medica, 2011
View PDFchevron_right
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
Robert Morlock
BMJ Open, 2019
View PDFchevron_right
GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
Michele Intorcia
Osteoporosis International, 2016
View PDFchevron_right
Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review
amna Iqbal
Cureus
View PDFchevron_right
Duration of Bisphosphonate Therapy for the Treatment of Osteoporosis
monica schonteich
2019
View PDFchevron_right
Efficacy, side-effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient preference and compliance: A critical review of published articles from 1970-2009
Charles Inderjeeth
Bone, 2010
View PDFchevron_right
Osteoporotic hip fractures: Bisphosphonates sales and observed turning point in trend. A population-based retrospective study
Carla Oliveira
Bone, 2013
View PDFchevron_right
Bone Turnover in Osteoporotic Women During Long-Term Oral Bisphosphonates Treatment: Implications for Treatment Failure and “Drug Holiday” in the Real World
Yair Liel
Endocrine Practice, 2017
View PDFchevron_right
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis
Gerd Möller
Rheumatology International, 2009
View PDFchevron_right
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
Christian Roux, Patrice Fardellone
Osteoporosis International, 2010
View PDFchevron_right
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
F. Ebetino
2010
View PDFchevron_right
Use of Oral Bisphosphonates in Primary Prevention of Fractures in Postmenopausal Women: A Population-Based Cohort Study
antonia lafarga
PLOS ONE, 2015
View PDFchevron_right
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year …
Gerd Möller
Rheumatology international, 2009
View PDFchevron_right
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention
John Schousboe MD PhD
Annals of Internal Medicine, 2019
View PDFchevron_right
Efficacy of Bisphosphonates for Preventing Osteoporotic Fracture in Postmenopausal Women: A Systematic Review and Meta – Analysis
Srisakun Sinsawad
2019
View PDFchevron_right
Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back
Mohammad Abdollahi
2012
View PDFchevron_right
Guideline concordance of bisphosphonates used for osteoporosis in a University Hospital, Thailand
Paphon Sa-ngasoongsong
2021
View PDFchevron_right